US ruling favours Teva Copaxone patents
This article was originally published in Scrip
Teva Pharmaceutical Industries has won an important ruling in its battle to defend its US patents for its multiple sclerosis drug Copaxone (glatiramer acetate). The markets certainly agreed as its shares were up on news that a federal judge rejected a motion to declare certain patents on the product invalid. The motion was brought by Novartis' Sandoz unit and Momenta Pharmaceuticals, who are seeking to launch a generic version before the expiry of US patents.